Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GP120-depleted HIV-1 vaccine

Drug Profile

GP120-depleted HIV-1 vaccine

Alternative Names: AG-1661; gp120 depleted HZ321 HIV-1; HIV vaccine - Immune Response; IR-8101; REMUNE; Remune Paediatric; RG-83894

Latest Information Update: 17 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Salk Institute
  • Developer Immune Response BioPharma
  • Class AIDS vaccines; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

  • 30 Oct 2019 Immune Response BioPharma announces intention to submit BLA to US FDA for HIV-1 infections (In infants, In children, In adolescents) in Q1 2020
  • 17 Sep 2018 GP120 depleted HIV-1 vaccine is available on expanded access (Immune Response BioPharma pipeline, September 2018)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in HIV-1-infections in Thailand (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top